Abstract:Lissencephaly is a developmental cortical malformation characterized by reduced to absent gyri and a disorganized cortex, often leading to severe impairments in affected individuals and a reduced life expectancy. Heterozygous mutations in the gene, encoding a regulator of the microtubule motor dynein, cause lissencephaly with different clinical severities. While the clinical disease spectrum correlates with the degree of lissencephaly, location and type of mutation may not. We leveraged forebrain-type organoids from LIS1-lissencephaly patients, diagnosed with mild, moderate or severe lissencephaly to investigate, in a cytoarchitecture and multi-omics approach, how the severity degree in patients might relate to specific mutations in the gene. We questioned which processes during cortical development might be differentially affected by severity grade, and whether they could be pharmacologically targeted. We found alterations in neurodevelopment often with a severity- dependent gradient. Specifically, we identified alterations of the cytoarchitecture, progenitor cell homeostasis and neurogenesis. Particularly important disease-linked molecular mechanisms were microtubule destabilization, WNT-signaling, and perturbed cadherin- and unfolded protein-binding. Some mechanisms exhibited a severity-dependent gradient, or were specific to a severe grade. We present strategies to reverse phenotypic changes in LIS1- patient organoids, and an approach with therapeutic potential. Thus, we show that different LIS1-severity grades can be recapitulated , that there is a direct link between the phenotype and genotype, that organoid-based disease modeling can identify molecular underpinnings of malformations of cortical development and that organoids provide a valid platform to develop and test therapeutic strategies.

Structures of human dynein in complex with the lissencephaly 1 protein, LIS1

Lis1 relieves cytoplasmic dynein-1 autoinhibition by acting as a molecular wedge

Coupling PAF signaling to dynein regulation: structure of LIS1 in complex with PAF-acetylhydrolase

Molecular mechanism of dynein-dynactin complex assembly by LIS1

Cryo-EM visualizes multiple steps of dynein activation pathway

De Novo Identification of Mammalian Ciliary Motility Proteins Using Cryo-Em

NudC-like Protein 2 Regulates the LIS1/dynein Pathway by Stabilizing LIS1 with Hsp90

Unraveling LIS1-Lissencephaly: Insights from Cerebral Organoids Suggest Severity- Dependent Genotype-Phenotype Correlations, Molecular Mechanisms and Therapeutic Strategies

Quantitative analysis of Pac1/LIS1-mediated dynein targeting: Implications for regulation of dynein activity in budding yeast

Opposing Effects of Ndel1 and Α1 or Α2 on Cytoplasmic Dynein Through Competitive Binding to Lis1

Conserved roles for the dynein intermediate chain and Ndel1 in assembly and activation of dynein

Three-dimensional regulation of radial glial functions by Lis1-Nde1 and dystrophin glycoprotein complexes

Multiple dose-dependent effects of Lis1 on cerebral cortical development

Dimerization of elongator protein 1 is essential for Elongator complex assembly

Nde1 promotes Lis1-mediated activation of dynein

A force-sensitive mutation reveals a non-canonical role for dynein in anaphase progression

Structure and mechanism of LARGE1 matriglycan polymerase

Novel lissencephaly-associated NDEL1 variant reveals distinct roles of NDE1 and NDEL1 in nucleokinesis and human cortical malformations

Cryoelectron Tomography Reveals Doublet-Specific Structures and Unique Interactions in the I1 Dynein

Patient-specific mutation of Dync1h1 in mice causes brain and behavioral deficits

Phosphorylation and Pin1 binding to the LIC1 subunit selectively regulate mitotic dynein functions